These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34082107)

  • 21. Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients.
    Matboli M; Shafei AE; Azazy AE; Reda M; El-Khazragy N; Nagy AA; Ali MA; Sobhi M; Abdel-Rahman O
    Biomark Med; 2018 Feb; 12(2):129-139. PubMed ID: 29338319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
    BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis.
    Weber DG; Casjens S; Johnen G; Bryk O; Raiko I; Pesch B; Kollmeier J; Bauer TT; Brüning T
    PLoS One; 2014; 9(12):e114483. PubMed ID: 25469901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.
    Wang Y; Jiang Z; Yan J; Ying S
    Dis Markers; 2019; 2019():4183157. PubMed ID: 30891101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
    Mäki-Nevala S; Sarhadi VK; Knuuttila A; Scheinin I; Ellonen P; Lagström S; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuutila S
    Lung; 2016 Feb; 194(1):125-35. PubMed ID: 26463840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylation analysis for multiple gene promoters in non-small cell lung cancers in high indoor air pollution region in China.
    Huang X; Wu C; Fu Y; Guo L; Kong X; Cai H
    Bull Cancer; 2018 Sep; 105(9):746-754. PubMed ID: 30126609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNAs diagnostic and prognostic value as predictive markers for malignant mesothelioma.
    Sturchio E; Berardinelli MG; Boccia P; Zanellato M; Gioiosa S
    Arch Environ Occup Health; 2020; 75(8):471-482. PubMed ID: 32308151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.
    Ren R; Yin P; Zhang Y; Zhou J; Zhou Y; Xu R; Lin H; Huang C
    Oncotarget; 2016 Dec; 7(51):84851-84859. PubMed ID: 27769044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA methylation profile of 28 potential marker loci in malignant mesothelioma.
    Tsou JA; Galler JS; Wali A; Ye W; Siegmund KD; Groshen S; Laird PW; Turla S; Koss MN; Pass HI; Laird-Offringa IA
    Lung Cancer; 2007 Nov; 58(2):220-30. PubMed ID: 17659810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
    Martínez-Rivera V; Negrete-García MC; Ávila-Moreno F; Ortiz-Quintero B
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer.
    Walter RFH; Rozynek P; Casjens S; Werner R; Mairinger FD; Speel EJM; Zur Hausen A; Meier S; Wohlschlaeger J; Theegarten D; Behrens T; Schmid KW; Brüning T; Johnen G
    PLoS One; 2018; 13(5):e0195716. PubMed ID: 29851970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibulin-3 as biomarker of malignant mesothelioma.
    Ledda C; Caltabiano R; Vella F; Matera S; Marconi A; Loreto C; Rapisarda V
    Biomark Med; 2019 Jul; 13(10):875-886. PubMed ID: 31237454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA methylation profiling of asbestos-treated MeT5A cell line reveals novel pathways implicated in asbestos response.
    Casalone E; Allione A; Viberti C; Pardini B; Guarrera S; Betti M; Dianzani I; Aldieri E; Matullo G
    Arch Toxicol; 2018 May; 92(5):1785-1795. PubMed ID: 29523930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of miR-222 and miR-126 regulation and its role in asbestos-induced malignancy.
    Gaetani S; Monaco F; Alessandrini F; Tagliabracci A; Sabbatini A; Bracci M; Valentino M; Neuzil J; Amati M; Santarelli L; Tomasetti M
    Int J Biochem Cell Biol; 2020 Apr; 121():105700. PubMed ID: 32006662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
    Wu D; Hiroshima K; Matsumoto S; Nabeshima K; Yusa T; Ozaki D; Fujino M; Yamakawa H; Nakatani Y; Tada Y; Shimada H; Tagawa M
    Am J Clin Pathol; 2013 Jan; 139(1):39-46. PubMed ID: 23270897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients.
    Hylebos M; Op de Beeck K; Pauwels P; Zwaenepoel K; van Meerbeeck JP; Van Camp G
    Lung Cancer; 2018 Oct; 124():19-22. PubMed ID: 30268460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
    Betti M; Casalone E; Ferrante D; Aspesi A; Morleo G; Biasi A; Sculco M; Mancuso G; Guarrera S; Righi L; Grosso F; Libener R; Pavesi M; Mariani N; Casadio C; Boldorini R; Mirabelli D; Pasini B; Magnani C; Matullo G; Dianzani I
    Cancer Lett; 2017 Oct; 405():38-45. PubMed ID: 28687356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
    De Santi C; Pucci P; Bonotti A; Melaiu O; Cipollini M; Silvestri R; Vymetalkova V; Barone E; Paolicchi E; Corrado A; Lepori I; Dell'Anno I; Pellè L; Vodicka P; Mutti L; Foddis R; Cristaudo A; Gemignani F; Landi S
    Occup Environ Med; 2017 Jun; 74(6):456-463. PubMed ID: 28343162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
    Borczuk AC; Pei J; Taub RN; Levy B; Nahum O; Chen J; Chen K; Testa JR
    Cancer Biol Ther; 2016; 17(3):328-35. PubMed ID: 26853494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
    Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
    Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.